{"product_id":"global-gene-therapy-on-cardiovascular-disease-market-growth-status-and-outlook-2023-2029","title":"Global Gene Therapy On Cardiovascular Disease Market Growth (Status and Outlook) 2023-2029","description":"\u003cp\u003eGlobal Gene Therapy On Cardiovascular Disease Market Growth (Status and Outlook) 2023-2029\u003c\/p\u003e\n\n\u003cp\u003eGene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.\u003cbr\u003e\nAlthough several conventional small-molecule treatments are available for common cardiovascular problems, gene therapy is a potential treatment option for acquired and inherited cardiovascular diseases that remain with unmet clinical needs.\u003cbr\u003e\nLPI (LP Information)' newest research report, the “Gene Therapy On Cardiovascular Disease Industry Forecast” looks at past sales and reviews total world Gene Therapy On Cardiovascular Disease sales in 2022, providing a comprehensive analysis by region and market sector of projected Gene Therapy On Cardiovascular Disease sales for 2023 through 2029. With Gene Therapy On Cardiovascular Disease sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gene Therapy On Cardiovascular Disease industry.\u003cbr\u003e\nThis Insight Report provides a comprehensive analysis of the global Gene Therapy On Cardiovascular Disease landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M\u0026amp;A activity. This report also analyzes the strategies of leading global companies with a focus on Gene Therapy On Cardiovascular Disease portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gene Therapy On Cardiovascular Disease market.\u003cbr\u003e\nThis Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gene Therapy On Cardiovascular Disease and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gene Therapy On Cardiovascular Disease.\u003cbr\u003e\nThe global Gene Therapy On Cardiovascular Disease market size is projected to grow from US$ 13 million in 2022 to US$ 1334.4 million in 2029; it is expected to grow at a CAGR of 94.4% from 2023 to 2029.\u003cbr\u003e\nGlobal key players of Gene Therapy On Cardiovascular Disease include Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals and Amgen, etc. Top three players occupy for a share about 76%. In terms of product, Non-Viral Gene Therapy is the largest segment, with a share over 100%. In terms of application, Vascular Disease is the largest market, with a share over 100%.\u003cbr\u003e\nThis report presents a comprehensive overview, market shares, and growth opportunities of Gene Therapy On Cardiovascular Disease market by product type, application, key players and key regions and countries.\u003cbr\u003e\nMarket Segmentation:\u003cbr\u003e\nSegmentation by type\u003cbr\u003e\nViral Gene Therapy\u003cbr\u003e\nNon-Viral Gene Therapy\u003cbr\u003e\nSegmentation by application\u003cbr\u003e\nHeart Disease\u003cbr\u003e\nVascular Disease\u003cbr\u003e\nThis report also splits the market by region:\u003cbr\u003e\nAmericas\u003cbr\u003e\nUnited States\u003cbr\u003e\nCanada\u003cbr\u003e\nMexico\u003cbr\u003e\nBrazil\u003cbr\u003e\nAPAC\u003cbr\u003e\nChina\u003cbr\u003e\nJapan\u003cbr\u003e\nKorea\u003cbr\u003e\nSoutheast Asia\u003cbr\u003e\nIndia\u003cbr\u003e\nAustralia\u003cbr\u003e\nEurope\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nUK\u003cbr\u003e\nItaly\u003cbr\u003e\nRussia\u003cbr\u003e\nMiddle East \u0026amp; Africa\u003cbr\u003e\nEgypt\u003cbr\u003e\nSouth Africa\u003cbr\u003e\nIsrael\u003cbr\u003e\nTurkey\u003cbr\u003e\nGCC Countries\u003cbr\u003e\nThe below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.\u003cbr\u003e\nBiogen\u003cbr\u003e\nNovartis\u003cbr\u003e\nGilead Sciences\u003cbr\u003e\nSarepta Therapeutics\u003cbr\u003e\nAlnylam Pharmaceuticals\u003cbr\u003e\nAmgen\u003cbr\u003e\nSpark Therapeutics\u003cbr\u003e\nAkcea Therapeutics\u003cbr\u003e\nbluebird bio\u003cbr\u003e\nSunway Biotech\u003cbr\u003e\nSIBIONO\u003cbr\u003e\nAnGes\u003cbr\u003e\nOrchard Therapeutics\u003cbr\u003e\nHuman Stem Cells Institute\u003c\/p\u003e\n\n\u003cp\u003ePlease note: The report will take approximately 2 business days to prepare and deliver.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"January, 2023 \/ 103 Pages \/ MCW16226210","offer_id":47640125145394,"sku":null,"price":4392.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-gene-therapy-on-cardiovascular-disease-market-growth-status-and-outlook-2023-2029","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}